Skip to main content
AmigoFish

Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

From BioCentury This Week · · 38 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentury This Week podcast, BioCentury’s Stephen Hansen breaks down the near-term and long-term outlook (https://www.biocentury.com/article/659014) for a biotech industry hoping to continue the growth of 2H25. BioCentury’s analysts also discuss the impact of the Trump administration’s tariffs (https://www.biocentury.com/article/659034) on the biopharma industry and last week’s biggest deals: the pending $6.3 billion takeout (https://www.biocentury.com/article/658982) of Centessa by Eli Lilly and the proposed $5.6 billion acquisition (https://www.biocentury.com/article/658981) of Apellis by Biogen. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech (https://www.iqviabiotech.com/).

Register now as a delegate or apply to join the 2026 Presenting Company Class before the 26th Bio€quity Europe (https://conferences.biocentury.com/bioequity-europe) May 4-6 in Prague sells out.

View full story: https://www.biocentury.com/article/659040

#BiotechMarkets #BiotechMA #GlobalVolatility #DrugPricingPolicy #BiopharmaStrategy

00:01 - Sponsor Message: IQVIA Biotech 05:09 - 2Q26 Preview 17:09 - Pharma Tariffs 24:04 - C-Path Initiative 26:32 - Lilly Deal 32:19 - Biogen Deal

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)

Back to BioCentury This Week · Report a problem